Targeting c-Abl/Drp1-Dependent Mitochondrial Fission: Neuroprotective Effects of Berberine Chloride in Parkinson’s Disease Models
Objective: To investigate the neuroprotective potential of berberine chloride in Parkinson’s disease (PD) by modulating pathological mitochondrial fission through c-Abl–mediated Drp1 phosphorylation using integrated bioinformatics,…Machine Learning-Driven Analysis of Epigenetic Signatures in Juvenile Huntington’s Disease: Investigating Histone Modification Dynamics
Objective: To investigate the role of histone modifications in Juvenile Huntington’s Disease (JHD) using machine learning, aiming to identify novel epigenetic biomarkers predictive of disease…Molecular Studies Reveal Overactive Interferon (IFN) Pathway in Two Monogenic Inherited Dystonia Types.
Objective: Our overall objective was to investigate the involvement of type I interferons (IFNs) in DYT-PRKRAand DYT-EIF2AK2. IFNs are antiviral cytokines produced by all cell…A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease
Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…Disease Modifying Potential of a Novel ROCK Inhibitor in Rodent Models of Synucleinopathy
Objective: Evaluate the impact of a novel Rho-associated kinase (ROCK) inhibitor on alpha-synuclein (a-syn) pathology, neuroinflammation, and dopamine neurodegeneration in the AAV-a-syn overexpression and a-syn…Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein
Objective: Objective: To investigate Neurotinib, a newly developed allosteric c-Abl inhibitor, as a neuroprotective agent in a murine GBA1-associated Parkinson's disease (PD) model. Background: The…Gut Microbiota May Alter Glucose Metabolism in Patients with Parkinson’s Disease
Objective: To compare the gut microbiota in patients with Parkinson’s disease (PD) and healthy controls and predict the functional pathways associated with these differences. Background:…Cognitive Outcome in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Treated with Deep Brain Stimulation (DBS):Case Report
Objective: To assess cognitive outcome in PKAN treated with DBS Background: PKAN is a rare neurodegenerative disorder with pediatric onset & dystonic features. Motor symptoms…The 201 Trial in Untreated Parkinson’s Disease
Objective: To evalute the safety, tolerability, clinical benefit and protein pathology status following risvodetinib (IkT-148009) treatment in participants with untreated Parkinson's disease. Background: RIsvodetinib is…Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.